Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-and-Multiple-Ascending Subcutaneous Doses of DR10624

NCT05378893 is registered in ClinicalTrials.gov with Zhejiang Doer Biologics Co., Ltd. as lead sponsor.

NCT NCT05378893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05378893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-and-Multiple-Ascending Subcutaneous Doses of DR10624
Lead sponsor
Zhejiang Doer Biologics Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 22, 2022
Completion date
January 31, 2025
Enrollment
153 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, obesity, metabolically